Equity Research Report: Anthem Biosciences Ltd.
Date: February 7, 2026
Current Market Price (CMP): ₹652.90 (Source: NSE/BSE Close, Feb 6, 2026)
Market Cap: ~₹36,690 Cr
Sector: Pharmaceuticals / CDMO (Contract Development & Manufacturing)
1️⃣ Business Model & Work
- Core Business: Anthem Biosciences ek leading Integrated CRDMO (Contract Research, Development, and Manufacturing Organization) hai. Ye pharmaceutical aur biotech companies ke liye drug discovery se lekar commercial manufacturing tak ki services provide karti hai.
- Unique Selling Proposition (USP): Anthem India ki un gini-chuni companies me se hai jo Chemistry (Small Molecules) aur Biology (Fermentation/Biologics) dono me massive scale par kaam karti hai.
- Revenue Segments:
- CRDMO Services (~79%): Drug discovery, development, aur manufacturing services.
- Specialty Ingredients (~21%): Nutraceuticals, probiotics, aur pharmaceutical intermediates ki manufacturing.
- Export Focus: Revenue ka bada hissa US, Europe aur Japan se aata hai.
- Competitive Edge: Inke paas India ki one of the largest Fermentation Capacities (142+ KL) hai, jo complex biological drugs banane ke liye zaroori hai.
2️⃣ Industry & Sector Analysis
- Sector Status: Structural Growth. Global Pharma companies “China+1” strategy ke tehat India me manufacturing shift kar rahi hain.
- Biosecure Act Impact: US ka “Biosecure Act” Chinese CDMOs (like WuXi AppTec) par restrictions laga raha hai, jiska seedha fayda Anthem jaise Indian players ko mil raha hai.
- Current Headwinds: Global biotech funding me thodi kami (funding winter) aayi hai, jisse early-stage discovery projects ki demand temporary slow hui hai.
3️⃣ Latest Financial Performance (Consolidated)
Data Source: Exchange Filings (Q3 FY26 Results declared Feb 5, 2026).
Note: Q3 FY26 ke results mixed hain. Revenue me girawat aayi hai lekin margins strongly improve huye hain.
| Particulars (₹ Cr) | Q3 FY26 (Dec ’25) | Q3 FY25 (Dec ’24) | YoY Growth | 9M FY26 (Apr-Dec) |
| Revenue | 423 | 498 | -15.0% 🔻 | 1,513 (+11%) |
| EBITDA | 191 | 184 | +3.7% 🔼 | 671 (+22%) |
| EBITDA Margin | 41.8% | 35.2% | +660 bps 🔼 | 41.5% |
| Net Profit (PAT) | 93 | 124 | -25.3% 🔻 | 402 (+9%) |
| EPS (₹) | 1.65 | 2.21 | -25% | 7.16 |
- Key Insight (Why PAT dropped?):
- Revenue Dip: CRDMO segment revenue 19% gira hai due to high base effect last year.
- One-time Hit: Profit me badi girawat ₹25.4 Cr ke Exceptional Item ki wajah se hai (Provisions for new Labour Codes). Agar isse hata dein, to profit stable hota.
- Positive: EBITDA Margin 41.8% par pahunch gaya hai, jo industry me best-in-class hai (Syngene se better).
4️⃣ Management & Shareholding (Latest – Dec 2025)
- Promoter Holding: 74.69% (Very High). Promoters (Ajay Bhardwaj & Team) ne IPO (July 2025) ke baad apna stake tightly hold kiya hua hai.
- FIIs (Foreign Investors): 1.36%. Foreign ownership abhi kam hai lekin recently listed company ke liye normal hai.
- DIIs (Domestic Investors): 7.60%. Mutual Funds ne IPO ke baad significant stake buy kiya hai, jo long-term trust dikhata hai.
- Management Quality: Founder Ajay Bhardwaj ex-Biocon hain. Management conservative guidance deti hai aur technical execution me strong track record hai.
5️⃣ Valuation (As of Feb 7, 2026)
- Current PE (TTM): ~73x
- Peer Comparison:
- Syngene International: ~55x PE (Larger, more stable but slower growth).
- Suven Pharma: ~60x PE.
- Divi’s Lab: ~65x PE (API giant).
- Valuation View: Anthem ka valuation Premium hai (Industry average se upar). Market ise “Scarcity Premium” de raha hai kyunki iske paas unique biology capabilities hain.
- Fair Value: Current financials ke hisab se stock Fully Valued lagta hai. Koi bhi badi growth disappointment stock price ko correct kar sakti hai.
6️⃣ Future Growth Triggers (3–5 Years)
- GLP-1 Opportunity: Weight-loss drugs (like Ozempic/Wegovy) ki global demand explode ho rahi hai. Anthem peptide synthesis aur fermentation capabilities ke saath is wave ko ride karne ke liye taiyar hai.
- Capacity Expansion (Unit 4): Company massive capex kar rahi hai nayi facility (Unit 4) ke liye, jo FY27 se revenue contribute karna shuru karegi.
- Animal Health: Company animal-free gelatin aur other niche products par kaam kar rahi hai jo high-margin business hai.
7️⃣ Present Situation (Outlook)
- Recent Listing: Stock July 2025 me list hua tha (IPO Price ₹570). Current price (₹653) IPO price se ~15% upar hai.
- Current Trend: Consolidation. Q3 result ke revenue miss ke baad stock thoda pressure me reh sakta hai.
- Short-term View: Range bound ₹600 – ₹680. Investors next quarter ki guidance ka wait karenge.
- Long-term View: Bullish. China-substitute theme aur biological capabilities Anthem ko 3-5 saal me multibagger potential deti hain.
8️⃣ Risk & Red Flags
- ⚠️ Client Concentration: Top 10 clients revenue ka bada hissa contribute karte hain. Kisi ek bade client ka project cancel hona nuksan de sakta hai.
- ⚠️ Biotech Funding Winter: Agar global markets me interest rates high rahe, to choti biotech companies R&D spend kam kar dengi, jiska asar Anthem ke revenue par padega.
- ⚠️ Regulatory Risk: USFDA audits me agar koi negative observation (Form 483) aati hai, to stock price 20-30% gir sakta hai (Pharma sector nature).
9️⃣ Final Verdict
- Summary: Anthem Biosciences ek High Quality, High Growth company hai jo India ke CDMO boom ka perfect proxy hai. Q3 ka weak revenue ek temporary blip lag raha hai, structural story intact hai.
- Conservative Investor: Wait for correction. Valuation (73x PE) abhi expensive hai. ₹580-600 ke levels ka wait karein.
- Aggressive Investor: Accumulate on Dips. Current price par small allocation start kar sakte hain, aur har 5-10% girawat par add karein.
- Target Range: Upside potential ₹850+ (18-24 months) driven by earnings growth from new capacity.
Disclaimer: Ye article sirf educational purpose ke liye hai. Kisi bhi nivesh se pehle apne Financial Advisor se salah zarur lein.